Skip to main content

Table 4 Xanthine oxidoreductase-inhibitory activities of topiroxostat and its metabolites in patients at week 52

From: Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis

 

IC50 a (μmol/L)

Relative ratio of IC50 b

Plasma concentrationc (μmol/L)

Concentrationd (μmol/L)

Topiroxostat

0.069

1

0.152

0.152

N-Oxide

13

1/188

0.0952

0.0005

N 1-Glucuronide

>100

1/1449

2.77

0.002

N 2-Glucuronide

>100

1/1449

0.686

0.0005

  1. aHalf maximal (50 %) xanthine oxidoreductase (XOR)-inhibitory concentration
  2. bThe relative ratio of IC50 between topiroxostat and its metabolites
  3. cPre-hemodialysis plasma concentrations of topiroxostat and its metabolites at week 52
  4. dEstimated plasma concentrations based on the relative ratio of IC50 between topiroxostat and its metabolites
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us